Filing Details

Accession Number:
0001209191-20-028839
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-13 16:38:52
Reporting Period:
2020-05-11
Accepted Time:
2020-05-13 16:38:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP Biological Products, (No Disgnostic Substances) (2836) 473173478
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1762583 Otto Lawrence Klein C/O Crispr Therapeutics, Inc.
610 Main Street
Cambridge MA 02139
Cbo & Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-05-11 25,000 $5.86 45,000 No 4 M Direct
Common Shares Disposition 2020-05-11 24,318 $60.38 20,682 No 4 S Direct
Common Shares Disposition 2020-05-11 682 $61.07 20,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2020-05-11 25,000 $0.00 25,000 $5.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,666 2026-03-01 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.025 to $61.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 43,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter.